EMA publishes procedural advice for biosimilars

Biosimilars/News | Posted 13/04/2012 post-comment0 Post your comment

On 11 April 2012, EMA published a new document on regulatory procedural advice for biosimilars.

picture 70

The guidance brings together a number of regulatory and procedural questions already published on the agency’s website in existing regulatory documents. It complements existing guidance documents on innovative products and should be read in conjunction with the agency’s scientific guidelines on biosimilars.

EMA is responsible for assessing applications from companies to market biological medicines for use in the EU, including biosimilars within the framework of the centralised authorisation procedure.

The document addresses a number of questions which users of the EU centralised authorisation procedure may have. It provides an overview of the EMA position on issues, which are typically addressed during the course of pre-submission meetings.

The document covers basic questions such as: what is a similar biological medicinal product and whether the biosimilar is eligible for evaluation under the centralised authorisation procedure, as well as more detailed subjects such as pharmacovigilance, risk management plans and interchangeability.

The procedural advice document is available on the EMA website:

EMA procedural advice for users of the centralised procedure for similar biological medicinal products applicationsEMA/940451/2011
Date: November 2011
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2012/04/WC500125166.pdf

EMA also recently published a draft concept paper for revision of the agency’s 2005 overarching guideline on similar biological medicinal products and a draft guideline on biosimilar medicines containing interferon beta (IFN-β). The concept paper was open for comment until February 2012 and EMA expects a draft revised guideline to be released in the first quarter of 2012 [1]. The draft guideline on IFN-β is available for comment until the end of May 2012 [2].

Related article

EU guidelines for biosimilars 

References

1.  GaBI Online - Generics and Biosimilars Initiative. EMA to revise overarching biosimilar guidelines [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2012 Apr 13]. Available from: www.gabionline.net/Guidelines/EMA-to-revise-overarching-biosimilar-guidelines

2.  GaBI Online - Generics and Biosimilars Initiative. EMA publishes draft biosimilar guideline for interferon beta [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2012 Apr 13]. Available from: www.gabionline.net/Guidelines/EMA-publishes-draft-biosimilar-guideline-for-interferon-beta

Source: EMA

comment icon Comments (0)
Post your comment
Related content
Canada approves pegfilgrastim biosimilar Armlupeg
Pegfilgrastim DrugBank V18K30
Biosimilars/News Posted 20/11/2024
FDA approves fifth ustekinumab biosimilar Imuldosa
11453696_l
Biosimilars/News Posted 13/11/2024
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010